Irm LLC
74 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Sep 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 24, 2027The maintenance fee for Markers Associated with WNT Inhibitors (US 10,422,007) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Compositions and Methods for Modulating FXR (US 9,150,568) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 2 fees due Jun 1 to 22, 2027 · next Jun 1
- 1 fee due Jul 19, 2027The maintenance fee for N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators (US 9,238,646) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 2 fees due Aug 6 to 13, 2027 · next Aug 6
- 2 fees due Oct 5, 2027
Recent changes
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,216,964 | Hedgehog Pathway Modulators In force · Medium confidence | In force | Medium confidence | |
| US 9,238,646 | N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators In force · High confidence | In force | High confidence | |
| US 9,469,645 | Compounds and Compositions for the Treatment of Parasitic Diseases In force · High confidence | In force | High confidence | |
| US 9,580,426 | Compounds That Expand Hematopoietic Stem Cells In force · High confidence | In force | High confidence | |
| US 9,365,506 | Compounds and Compositions as TLR2 Agonists In force · High confidence | In force | High confidence | |
| US 9,150,568 | Compositions and Methods for Modulating FXR In force · High confidence | In force | High confidence | |
| US 8,569,283 | Compounds and Compositions as C-Kit Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,199,981 | Compounds and Compositions as C-Kit Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,649,359 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | In force | High confidence | |
| US 9,301,971 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | In force | High confidence |
Also on record, not counted in the 16: 74 patents in force now held by others · 145 lapsed for an unpaid fee · 18 ended at full term · 1 past the fee grace period · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 22 abandoned · 140 no status recorded